A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Inclusion Criteria: * Willing and able to provide written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Documented histologically confirmed adenocarcinoma of the prostate * Willing to undergo prostatectomy as primary treatment for localized prostate cancer * High risk prostate cancer (per National Comprehensive Cancer Network \[NCCN\] criteria): Gleason score 8-10 or T3a or PSA \> 20 ng/mL or very-high risk prostate cancer (per NCCN criteria): T3b-T4 * Serum testosterone \>= 150 ng/dL * Able to swallow the study drugs whole * Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing) * Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug * Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry Exclusion Criteria: * Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy) * Prior use of apalutamide, abiraterone acetate or degarelix * Prior or…